Premium
Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis Patients—A Pilot Study
Author(s) -
Čabarkapa Andrea,
Živković Lada,
Borozan Sunčica,
ZlatkovićŠvenda Mirjana,
Dekanski Dragana,
Jančić Ivan,
RadakPerović Marija,
Bajić Vladan,
SpremoPotparević Biljana
Publication year - 2016
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5662
Subject(s) - methotrexate , rheumatoid arthritis , lipid peroxidation , dna damage , catalase , medicine , pharmacology , oxidative stress , cell damage , arthritis , immunology , gastroenterology , chemistry , biochemistry , dna
The effects of co‐administration of dry olive leaf extract (DOLE) with standard methotrexate (MTX) therapy on the parameters of cell damage and inflammation in patients with early and long‐term rheumatoid arthritis (RA) were evaluated at baseline, 3 and 6 weeks. Patients were assigned to groups: the early phase RA group on MTX monotherapy (E MTX), and the two RA groups that received co‐treatment with DOLE and MTX: early (E MTX + DOLE) and long‐term phase patients (L‐t MTX+ DOLE). Baseline values indicated increased parameters of cell damage and disruption of redox balance in all groups. After three weeks the E MTX + DOLE group maintained high catalase activity, exhibited decrease of lipid peroxidation and protein damage indicators—thiols and nitrites, while levels of DNA damage and pro‐inflammatory interleukin‐6 were significantly reduced. In E MTX group catalase activity remained unaltered while significant lipid peroxidation and DNA damage reductions were seen only after six weeks. L‐t MTX + DOLE group showed only modest alterations of cell damage parameters during six weeks. Combined administration of DOLE with MTX contributes to faster reduction of cell damage, restores oxidative balance and improves interleukin‐6 suppression during high disease activity in early phase RA, but not in long term patients. Copyright © 2016 John Wiley & Sons, Ltd.